Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria
- PMID: 28373189
- PMCID: PMC5444115
- DOI: 10.1128/AAC.02671-16
Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria
Abstract
The impact of bacterial species on outcome in bloodstream infections (BSI) is incompletely understood. We evaluated the impact of bacterial species on BSI mortality, with adjustment for patient, bacterial, and treatment factors. From 2002 to 2015, all adult inpatients with monomicrobial BSI caused by Staphylococcus aureus or Gram-negative bacteria at Duke University Medical Center were prospectively enrolled. Kaplan-Meier curves and multivariable Cox regression with propensity score models were used to examine species-specific bacterial BSI mortality. Of the 2,659 enrolled patients, 999 (38%) were infected with S. aureus, and 1,660 (62%) were infected with Gram-negative bacteria. Among patients with Gram-negative BSI, Enterobacteriaceae (81% [1,343/1,660]) were most commonly isolated, followed by non-lactose-fermenting Gram-negative bacteria (16% [262/1,660]). Of the 999 S. aureus BSI isolates, 507 (51%) were methicillin resistant. Of the 1,660 Gram-negative BSI isolates, 500 (30%) were multidrug resistant. The unadjusted time-to-mortality among patients with Gram-negative BSI was shorter than that of patients with S. aureus BSI (P = 0.003), due to increased mortality in patients with non-lactose-fermenting Gram-negative BSI generally (P < 0.0001) and Pseudomonas aeruginosa BSI (n = 158) in particular (P < 0.0001). After adjustment for patient demographics, medical comorbidities, bacterial antibiotic resistance, timing of appropriate antibiotic therapy, and source control in patients with line-associated BSI, P. aeruginosa BSI remained significantly associated with increased mortality (hazard ratio = 1.435; 95% confidence interval = 1.043 to 1.933; P = 0.02). P. aeruginosa BSI was associated with increased mortality relative to S. aureus or other Gram-negative BSI. This effect persisted after adjustment for patient, bacterial, and treatment factors.
Keywords: Gram negative; Pseudomonas aeruginosa; Staphylococcus aureus; bloodstream infections.
Copyright © 2017 American Society for Microbiology.
Figures

Similar articles
-
Prevalence and impact of multidrug-resistant bacteria in solid cancer patients with bloodstream infection: a 25-year trend analysis.Microbiol Spectr. 2024 Oct 3;12(10):e0296123. doi: 10.1128/spectrum.02961-23. Epub 2024 Aug 28. Microbiol Spectr. 2024. PMID: 39194256 Free PMC article.
-
Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections.Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01709-16. doi: 10.1128/AAC.01709-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 27993852 Free PMC article.
-
Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.Clin Infect Dis. 2015 Feb 15;60(4):539-48. doi: 10.1093/cid/ciu866. Epub 2014 Nov 6. Clin Infect Dis. 2015. PMID: 25378459
-
Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.Clin Microbiol Infect. 2019 Aug;25(8):964-970. doi: 10.1016/j.cmi.2019.04.005. Epub 2019 Apr 14. Clin Microbiol Infect. 2019. PMID: 30995530
-
Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.Curr Opin Microbiol. 2007 Oct;10(5):436-40. doi: 10.1016/j.mib.2007.07.004. Epub 2007 Aug 30. Curr Opin Microbiol. 2007. PMID: 17765004 Review.
Cited by
-
Topically applied bacteriophage to control multi-drug resistant Pseudomonas aeruginosa-infected wounds in a New Zealand rabbit model.Front Microbiol. 2022 Oct 18;13:1031101. doi: 10.3389/fmicb.2022.1031101. eCollection 2022. Front Microbiol. 2022. PMID: 36329839 Free PMC article.
-
Whole-transcriptome analysis reveals mechanisms underlying antibacterial activity and biofilm inhibition by a malic acid combination (MAC) in Pseudomonas aeruginosa.PeerJ. 2023 Dec 7;11:e16476. doi: 10.7717/peerj.16476. eCollection 2023. PeerJ. 2023. PMID: 38084141 Free PMC article.
-
Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancies.Infect Drug Resist. 2023 Jul 31;16:4943-4952. doi: 10.2147/IDR.S419064. eCollection 2023. Infect Drug Resist. 2023. PMID: 37546370 Free PMC article.
-
Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.Rev Esp Quimioter. 2018 Feb;31(1):78-100. Epub 2018 Feb 23. Rev Esp Quimioter. 2018. PMID: 29480677 Free PMC article. Review.
-
Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials.Microorganisms. 2023 Mar 31;11(4):916. doi: 10.3390/microorganisms11040916. Microorganisms. 2023. PMID: 37110338 Free PMC article. Review.
References
-
- Hernandez C, Cobos-Trigueros N, Feher C, Morata L, De La Calle C, Marco F, Almela M, Soriano A, Mensa J, Del Rio A, Martinez JA. 2014. Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome. Eur J Clin Microbiol Infect Dis 33:1973–1980. doi:10.1007/s10096-014-2146-3. - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources